ASP5502 / Astellas - LARVOL DELTA

Vitamin K3 attenuates STING-agonist-induced signaling and imiquimod-induced psoriasis-like inflammation. (PubMed, Biochem Pharmacol) - "Although several potent STING inhibitors are in preclinical development and ASP5502 has entered clinical evaluation, no STING inhibitor has received regulatory approval. Among the vitamin K analogues examined, VK3 showed the most consistent attenuation of STING-agonist-induced signaling. These findings support further investigation of VK3 as a topical modulator of inflammatory signaling in skin disease."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • CGAS • IL17A • IL23A • STING

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome (clinicaltrials.gov) - P1 | N=116 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Jul 2027 ➔ Mar 2026 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2027 ➔ Mar 2026; Company's strategic decision

Biomarker • Trial completion date • Trial primary completion date • Trial termination • Immunology • Sjogren's Syndrome

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Sjogren's Syndrome

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome (clinicaltrials.gov) - P1 | N=132 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

Biomarker • New P1 trial • Immunology • Sjogren's Syndrome